CLOs on the Move


 
Dkwd is a Aberdeen, SD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dkwd.com
  • 217 Railroad Ave SE
    Aberdeen, SD USA 57401
  • Phone: 314.727.3485

Executives

Name Title Contact Details

Similar Companies

Arizona BioIndustry Association

Arizona BioIndustry Association is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Flagler Hospital

Rich history mixed with innovative technology is an integral part of Flagler Hospital in historic St. Augustine, Florida. Since its founding in 1889, our private, not-for-profit facility has grown into a 335 bed, acute care center that is consistently recognized nationally for overall clinical excellence. The hospital has consistently ranked among the top 5% in the nation for clinical excellence and patient safety for nearly a decade and was Northeast Florida`s first hospital to receive the ANCC Magnet hospital award. Most recently, the hospital earned five stars for heart attack treatment, the Gold Seal of Approvalâ„¢ from The Joint Commission for Primary Stroke Care Centers, Center of Excellence Designation for its Bariatric Surgery Center, and national accreditation for total knee and total hip replacement surgery.

BodyTel

BodyTel is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Natural Partners

Natural Partners offers quality wholesale vitamins and supplements and a convenient way for health care practitioners to better serve their patients.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.